{"id":65282,"date":"2026-05-14T13:48:02","date_gmt":"2026-05-14T05:48:02","guid":{"rendered":"https:\/\/flcube.com\/?p=65282"},"modified":"2026-05-14T13:48:03","modified_gmt":"2026-05-14T05:48:03","slug":"beone-medicines-bcl2-inhibitor-beqalzi-sonrotoclax-receives-fda-fast-track-for-relapsed-mantle-cell-lymphoma-52-response-rate-in-phase-i-ii-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65282","title":{"rendered":"BeOne Medicines&#8217; BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study"},"content":{"rendered":"\n<p><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>), formerly BeiGene, announced that its self-developed <strong>BCL2 inhibitor Beqalzi (sonrotoclax)<\/strong> has received <strong>Fast Track designation<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of <strong>relapsed or refractory (R\/R) mantle cell lymphoma (MCL)<\/strong>. The indication covers patients who have received at least two prior lines of systemic therapy, including a <strong>Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-designations-amp-clinical-data-package\">Regulatory Designations &amp; Clinical Data Package<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>FDA Designation<\/th><th>Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Fast Track<\/strong><\/td><td>R\/R MCL (\u22652 prior therapies, including BTKi)<\/td><td>Granted<\/td><\/tr><tr><td><strong>Breakthrough Therapy<\/strong><\/td><td>R\/R MCL (\u22652 prior therapies, including BTKi)<\/td><td>Granted<\/td><\/tr><tr><td><strong>Orphan Drug<\/strong><\/td><td>R\/R MCL<\/td><td>Granted<\/td><\/tr><tr><td><strong>Fast Track<\/strong><\/td><td>Waldenstr\u00f6m&#8217;s macroglobulinemia (WM)<\/td><td>Granted<\/td><\/tr><tr><td><strong>Orphan Drug<\/strong><\/td><td>WM, multiple myeloma, AML, MDS<\/td><td>Granted<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pivotal-phase-i-ii-study-results-bgb-11417-201-nct05471843\">Pivotal Phase I\/II Study Results (BGB-11417-201, NCT05471843)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> R\/R MCL with \u22652 prior systemic therapies (including BTK inhibitor)<\/li>\n\n\n\n<li><strong>Overall Response Rate (ORR):<\/strong> <strong>52%<\/strong> (independent review committee-assessed)<\/li>\n\n\n\n<li><strong>Complete Response (CR) Rate:<\/strong> <strong>16%<\/strong><\/li>\n\n\n\n<li><strong>Median Duration of Response (DOR):<\/strong> <strong>15.8 months<\/strong><\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Generally well tolerated as monotherapy<\/li>\n\n\n\n<li><strong>Confirmatory Trial:<\/strong> Ongoing CELESTIAL-RRMCL (NCT06742996) for continued approval verification<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-approval-status-amp-commercial-strategy\">Global Approval Status &amp; Commercial Strategy<\/h2>\n\n\n\n<p><strong>China Approvals (Already Granted):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adult patients with <strong>Chronic Lymphocytic Leukemia (CLL)<\/strong> or <strong>Small Lymphocytic Lymphoma (SLL)<\/strong> who received \u22651 prior systemic therapy (including BTKi)<\/li>\n\n\n\n<li>Adult patients with <strong>R\/R MCL<\/strong> who received \u22652 prior systemic therapies (including BTKi)<\/li>\n<\/ul>\n\n\n\n<p><strong>U.S. Development Pathway:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Fast Track designation enables rolling review and priority regulatory interactions<\/li>\n\n\n\n<li>Breakthrough Therapy designation provides intensive FDA guidance and organizational commitment<\/li>\n\n\n\n<li>Continued approval contingent upon confirmatory trial results<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<p><strong>Mantle Cell Lymphoma Market Dynamics:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>R\/R MCL represents a high-unmet medical need with limited effective treatment options after BTK inhibitor failure<\/li>\n\n\n\n<li>Median overall survival in this population typically ranges from 12-24 months<\/li>\n\n\n\n<li>Current standard of care includes chemotherapy regimens with significant toxicity profiles<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Differentiation:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BCL2 inhibition mechanism<\/strong> offers targeted approach compared to conventional chemotherapy<\/li>\n\n\n\n<li><strong>52% ORR<\/strong> compares favorably to historical benchmarks in heavily pretreated R\/R MCL<\/li>\n\n\n\n<li><strong>15.8-month median DOR<\/strong> suggests durable clinical benefit<\/li>\n\n\n\n<li><strong>Oral administration<\/strong> provides patient convenience advantages over intravenous therapies<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Portfolio Positioning:<\/strong><br>BeOne&#8217;s sonrotoclax represents a key asset in the company&#8217;s transition from primarily partnered commercialization to proprietary product leadership. The drug&#8217;s broad orphan designations across multiple hematologic malignancies position it for potential label expansion beyond the initial MCL indication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications-amp-pipeline-value\">Financial Implications &amp; Pipeline Value<\/h2>\n\n\n\n<p>The FDA&#8217;s triple designation (Fast Track, Breakthrough Therapy, Orphan Drug) significantly de-risks the U.S. regulatory pathway and accelerates potential commercial launch timeline. With multiple orphan indications under development, sonrotoclax could become a multi-billion dollar franchise if approved across its full development portfolio.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical trial outcomes, and commercial expectations for sonrotoclax. Actual results may differ due to risks including confirmatory trial results, regulatory decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051400054_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051400054_c.\"><\/object><a id=\"wp-block-file--media-a92fc5c8-e598-489d-9c8b-fc0f2070bd38\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051400054_c.pdf\">2026051400054_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051400054_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a92fc5c8-e598-489d-9c8b-fc0f2070bd38\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that its self-developed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65284,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[185,2092,847,3046,15,848],"class_list":["post-65282","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-beigene","tag-beone-medicines","tag-hkg-6160","tag-nasdaq-onc","tag-product-approvals","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines&#039; BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that its self-developed BCL2 inhibitor Beqalzi (sonrotoclax) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The indication covers patients who have received at least two prior lines of systemic therapy, including a Bruton&#039;s tyrosine kinase (BTK) inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65282\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines&#039; BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that its self-developed BCL2 inhibitor Beqalzi (sonrotoclax) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The indication covers patients who have received at least two prior lines of systemic therapy, including a Bruton&#039;s tyrosine kinase (BTK) inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65282\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T05:48:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T05:48:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines&#8217; BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\\\/II Study\",\"datePublished\":\"2026-05-14T05:48:02+00:00\",\"dateModified\":\"2026-05-14T05:48:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282\"},\"wordCount\":494,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1402.webp\",\"keywords\":[\"BeiGene\",\"BeOne Medicines\",\"HKG: 6160\",\"NASDAQ: ONC\",\"Product approvals\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65282#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65282\",\"name\":\"BeOne Medicines' BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\\\/II Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1402.webp\",\"datePublished\":\"2026-05-14T05:48:02+00:00\",\"dateModified\":\"2026-05-14T05:48:03+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that its self-developed BCL2 inhibitor Beqalzi (sonrotoclax) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R\\\/R) mantle cell lymphoma (MCL). The indication covers patients who have received at least two prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65282\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1402.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines' BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\\\/II Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65282#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines&#8217; BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\\\/II Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines' BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that its self-developed BCL2 inhibitor Beqalzi (sonrotoclax) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The indication covers patients who have received at least two prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65282","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines' BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that its self-developed BCL2 inhibitor Beqalzi (sonrotoclax) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The indication covers patients who have received at least two prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.","og_url":"https:\/\/flcube.com\/?p=65282","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T05:48:02+00:00","article_modified_time":"2026-05-14T05:48:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65282#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65282"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines&#8217; BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study","datePublished":"2026-05-14T05:48:02+00:00","dateModified":"2026-05-14T05:48:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65282"},"wordCount":494,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65282#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402.webp","keywords":["BeiGene","BeOne Medicines","HKG: 6160","NASDAQ: ONC","Product approvals","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65282#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65282","url":"https:\/\/flcube.com\/?p=65282","name":"BeOne Medicines' BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65282#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65282#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402.webp","datePublished":"2026-05-14T05:48:02+00:00","dateModified":"2026-05-14T05:48:03+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that its self-developed BCL2 inhibitor Beqalzi (sonrotoclax) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The indication covers patients who have received at least two prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65282#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65282"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65282#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402.webp","width":1080,"height":608,"caption":"BeOne Medicines' BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65282#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines&#8217; BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma \u2013 52% Response Rate in Phase I\/II Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65282"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65282\/revisions"}],"predecessor-version":[{"id":65286,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65282\/revisions\/65286"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65284"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}